The analysis includes 868 men with raised PSA (≥3ng/mL and <10ng/mL) and histologically-confirmed prostate cancer that had information available on the 4 PSA-SNPs (828 (95.4%) localized (T1: 637, T2: 191), 40 (4.6%) missing stage; 684 (78.8%) low-grade, 184 (21.2%) high-grade; Low risk: 684 (78.8%); High risk: 184 (21.2%)). The gene discussed is KLK3; the disease is prostate cancer.